Mayo’s New Agreement Will Lead to First Commercialized Blood Test for Dementia

Mayo Clinic announced Tuesday that it has signed an agreement with Maryland-based A&G Pharmaceuticals that will ultimately pave the way for Mayo to offer the first commercial blood test to predict progranulin mutation status in patients suspected to havefrontotemporal dementia (FTD). Terms of the agreement were not disclosed.